Hebrew University drug trials show 50 percent cure rate in lab mice
Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemia patients for the past 40 years. Until now.
As published today in the scientific journal Cell, Professor Yinon Ben-Neriah and his research team at the Hebrew University of Jerusalem (HU)’s Faculty of Medicine have developed a new biological drug with a cure rate of 50% for lab mice with acute leukemia.
Leukemia produce a variety (and a high quantity) of proteins that together provide leukemic cells with rapid growth and death protection from chemotherapy.
To date, most of the biological cancer drugs used to treat leukemia target only individual leukemic cell proteins. However, during “targeted therapy” treatments, leukemic cells quickly activate their other proteins to block the drug. The result is drug-resistant leukemic cells which quickly regrow and renew the disease.
However, the new drug developed by Ben-Neriah and his team functions like a cluster bomb. It attacks several leukemic proteins at once, making it difficult for the leukemia cells to activate other proteins that can evade the therapy. Further, this single molecule drug accomplishes the work of three or four separate drugs, reducing cancer patients need to be exposed to several therapies and to deal with their often unbearable side-effects.
Additionally promising, is the new drug’s ability to eradicate leukemia stem cells. This has long been the big challenge in cancer therapy and one of the main reasons that scientists have been unable to cure acute leukemia.
“We were thrilled to see such a dramatic change even after only a single dose of the new drug. Nearly all of the lab mice’s’ leukemia signs disappeared overnight,” shared professor Ben-Neriah.
BioTheryX recently bought the rights to this promising drug from HU’s technology transfer company Yissum. Together with Ben-Neriah’s research team, they are now applying for FDA approval for phase I clinical studies.
Learn more: For first time in 40 years, cure for acute leukemia within reach
The Latest on: Acute myeloid leukemia
[google_news title=”” keyword=”acute myeloid leukemia” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Acute myeloid leukemia
- Working out of a jam: Sanders family turns to faith, baseball while overcoming medical emergencieson April 26, 2024 at 5:00 pm
It took our legs right out from under us as a family. It completely caught us off guard.” Evan Sanders was diagnosed with acute myeloid leukemia. “It was a little scary at first, but I kept saying ...
- The lucky ones: Former world champion’s life was saved by a clinical trial. Now she wants others to get the chance.on April 26, 2024 at 6:48 am
A world champion triathlete, Siri Lindley now lobbies to make medical trials, like the one that that cured her leukemia, more accessible ...
- Deverra Therapeutics Granted FDA Fast Track Designation for DVX101 (Dilanubicel) for the Treatment of Acute Myeloid Leukemiaon April 24, 2024 at 1:30 pm
Designation Validates Preliminary Data and Supports Accelerated Drug Development SEATTLE, WA / ACCESSWIRE / April 24, 2024 / , Inc., a clinical-stage biotechnology company developing allogeneic ...
- Is the FDA Pressing Pause on More Cancer Trials? It's Hard to Tellon April 24, 2024 at 6:41 am
Clinical trial holds delay therapies getting to market and may be on the rise in oncology. But there's a lot the public doesn't know about how often these holds happen and why.
- Ziftomenib Granted Breakthrough Therapy Designation by FDA in R/R AMLon April 23, 2024 at 8:00 am
The investigational drug ziftomenib is currently being evaluated for patients with relapsed/refractory NPM1-mutant acute myeloid leukemia.
- Students, staff rally around Fairfield teacher and coach diagnosed with leukemiaon April 23, 2024 at 6:48 am
FAIRFIELD, Ohio (WKRC) - Eric Richmond is a beloved teacher, Fairfield JV basketball coach, and fiancé. He is admired by many at Fairfield High School, including the varsity basketball coach, D.J.
- Acute Myeloid Leukemiaon April 22, 2024 at 4:59 pm
Newly diagnosed patients with FLT3-mutated acute myeloid leukemia showed improvements after receiving crenolanib plus chemotherapy in a recent study. As a comfort care companion for Moffitt Cancer ...
- New CAR T Cell Clinical Trial for Acute Myeloid Leukemia Is First of Its Kindon April 21, 2024 at 9:00 pm
Acute myeloid leukemia (AML) is one of the most challenging blood cancers. The disease moves quickly and needs aggressive treatment with chemotherapy, sometimes followed by a bone marrow transplant.
- Potential new treatment strategy for aggressive leukemiaon April 18, 2024 at 7:11 am
Scientists have found a potential treatment strategy for an aggressive type of leukemia by targeting enzymes used by cells to sense and adapt to oxygen levels.
- Acute Myeloid Leukemia Market Size is Expected to Grow by 2032 | DelveInsighton April 15, 2024 at 11:56 am
As per DelveInsight analysis, the Acute Myeloid Leukemia market is anticipated to witness growth at a considerable CAGR.
via Bing News